Abstract
Atrial flutter (AFL) is an arrhythmia which occurs frequently. Epidemiological data show an incidence of 88/100 000 new cases per year in the general population in USA, with 200 000 new cases every year [1]. The main predictors of this arrhythmia are heart failure and chronic obstructive pulmonary disease. It often coexists with atrial fibrillation (AF); moreover, it is not unusual that patients undergoing antiarrhythmic treatment with class IC drugs or amiodarone for the treatment of AF develop episodes of AFL. Often AFL is poorly tolerated due to the high ventricular response. This happens even in patients with good control of ventricular rate at rest, who do not tolerate AFL during effort, since ventricular rate increases suddenly.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Granada J, Uribe W, Cyhou PH et al (2000) Incidence and predictors of atrial flutter in the general population. J Am Coll Cardiol 36:2242–2246
Natale A, Newby KH, Pisanö E et al (2000) Prospective randomized comparison of antiarrhythmic therapy versus first-line radiofrequency ablation in patients with atrial flutter. J Am Coll Cardiol 35:1898–1904
Bianconi L, Boccadamo R, Pappalardo A et al (1989) Effectiveness of intravenous propafenone for conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am J Cardiol 64:335–338
Suttorp MJ, Kingma JH, Lie-A-Huen L et al (1989) Intravenous flecainide versus verapamil for conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am J Cardiol 63:693–696
Antman EM, Beamer Ad, Cantillon C et al (1990) Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs. J Am Coll Cardiol 15:698–707
Olshansky B (1996) Dofetilide versus quinidine for atrial flutter: vive 1a difference. J Cardiovasc Electrophysiol 7:809–827
Falk RH, Pollak A, Singh SN et al (1997) Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. J Am Coll Cardiol 29:385–390
Suttorp MJ, Polak PE, Van’t-Hof A et al (1992) Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter. Am J Cardiol 69:417–418
Bianconi L, Dinelli L, Papalardo A et al (1995) Comparison of intravenously-administered dofetilide vs amiodarone in the acute termination of atrial fibrillation and flutter: a multi-centered randomized, double-blind placebo-controlled study. Circulation 92(Suppl 1):1–775
Singh S, Berk M, Zoble R et al (1998) Oral dofetilide for conversion of patients with chronic atrial fibrillation or atrial flutter to normal sinus rhythm: a multicenter study. J Am Coll Cardiol 31 (Suppl A):369A–370A
Ellenbogen KA, Stambler BS, Wood MA et al (1996) Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 28:130–136
Naccarelli GV, Lee KS, Gibson GK, VanderLugt J (1996) Electrophysiology and pharmacology of ibutilide. Am J Cardiol 78(suppl 8A):12–16
Stambler BS, Wood MA, Ellenbogen KA et al (1996) Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 94:1613–1621
Murray KT (1998) Ibutilide. Circulation 97:493–497
Kowey PR, VanderLugt JT, Luderer JR (1996) Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter. Am J Cardiol 78(Suppl 8A):46–52
Kowey PR (1997) Use of ibutilide following cardiac surgery. J Am Coll Cardiol 98:633
Abi-Mansour P, Carberry PA, McCowan RJ et al (1998) Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. Study investigator. Am Heart J 136:632–642
Haft JL, Kosowsky BD, Lau SH et al (1967) Termination of atrial flutter by electrical pacing of the atrium. Am J Cardiol 20:229
Feld GK, Fleck, Chen PS et al (1992) Radiofrequency catheter ablation for the treatment of human type I atrial flutter: identification of a critical zone in the reentrant circuit by endocardial mapping technique. Circulation 86:1233
Delia Bella P, Marenzi G, Tondo C et al (1989) Effects of disopyramide on cycle length, effective refractory period and excitable gap of atrial flutter, and relation to arrhythmia termination by overdrive pacing. Am J Cardiol 63:812–816
Olshansky B, Okomura K, Hess PG et al (1988) Use of procainamide with rapid atrial pacing for successful conversion of atrial flutter to sinus rhythm. J Am Coll Cardiol 11:359–364
Doni F, Delia Bella P, Kheir A et al (1995) Atrial flutter termination by overdrive transesophageal pacing and the facilitating effect of oral propafenone. Am J Cardiol 76:1243–1246
D’Este D, Bertaglia M, Mantovan R et al (1997) Efficacy of intravenous propafenone in termination of atrial flutter by overdrive transesophageal pacing previously ineffective. Am J Cardiol 79:500–502
Heldal M, Orning OM (1993) Effects of flecainide on termination of atrial flutter by rapid atrial pacing. Eur Heart J 14:421–424
Stambler BS, Wood MA, Ellenbogen KA (1996) Comparative efficacy of intravenous ibutilide versus procainamide for enhancing termination of atrial flutter by atrial overdrive pacing. Am J Cardiol 77:960–966
Vincenti A, Cirö A, De Ceglia S et al (2001) Predictors of failure of transoesophageal cardioversion of common atrial flutter. Europace 3:10–15
Chung DC, Kerr CR, Cooper J (1987) Termination of spontaneous atrial flutter by transesophageal pacing. Pacing Clin Electrophysiol 10:1147
Guarnerio M, Furlanello F, Del Greco M et al (1989) Transesophageal atrial pacing: a first choice technique in atrial flutter therapy. Am Heart J 117:1241
Kantharia BK, Mookherjee S (1995) Clinical utility and the predictors of outcome of overdrive atrial transesophageal atrial pacing in the treatment of the atrial flutter. Am J Cardiol 76:144–147
Raviele A, Bonso A, Gasparini G et al (1999) Ibutilide for cardioversion of atrial fibrillation: how effective and safe is it? In: Raviele A (ed) Cardiac arrhythmias. Springer, Milan, pp 186–190
Tai CT, Chen SA, Feng AN et al (1998) Electropharmacologic effects of class I and class III antiarrhythmia drugs on typical atrial flutter: insights into the mechanism of termination. Circulation 19:1935–1945
Fera MS, Mazza A, Bettiol F et al (2001) Ibutilide versus transesophageal atrial pacing for atrial flutter treatment. Europace 2(suppl):A17
Rossillo A, Bonso A Themistoclakis S et al (2002) Confronto tra studio elettrofisiologico transesofageo e ibutilide nella riconversione delle aritmie atriali sincronizzate. Ital Heart J 3(suppl): 173S
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Italia
About this paper
Cite this paper
Bonso, A., Themistoclakis, S., Rossillo, A., Raviele, A. (2004). Acute Termination of Atrial Flutter: Class III Drugs or Transesophageal Pacing?. In: Raviele, A. (eds) Cardiac Arrhythmias 2003. Springer, Milano. https://doi.org/10.1007/978-88-470-2137-2_34
Download citation
DOI: https://doi.org/10.1007/978-88-470-2137-2_34
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-2177-8
Online ISBN: 978-88-470-2137-2
eBook Packages: Springer Book Archive